Casi Pharmaceuticals (CASI)

[Rocky I]

CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma (OCCC)
Antitumor Activity, Safety and Predictive Biomarker Results to be Presented
ROCKVILLE, Md., June 1, 2016 - CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces a poster presentation on ENMD-2076 at the American Society of Clinical Oncology Annual Meeting. ENMD-2076 is currently in a Phase 2 trial for the treatment of ovarian clear cell carcinoma (OCCC) at Princess Margaret Hospital Centre in Toronto. ASCO will be held June 3 – 7, 2016 in Chicago. The poster will be presented in the session listed below and will be available on the CASI Pharmaceuticals website afterward.

Gynecologic Cancer:
General Poster Session
Monday, June 6, 2016, 1:00PM – 4:30PM (CDT)
Abstract No.: 5564, Poster Board No.: 387
Title: Antitumor Activity, Safety and Predictive Biomarker Results of ENMD-2076 Administered to Patients (pts) with Recurrent Ovarian Clear Cell Carcinoma (OCCC): A Trail of the Princess Margaret Phase II Consortium
Location: Hall A